Just because we're in the market's worst month of the year doesn't mean there aren't good investments available.

But James "Rev Shark" Deporre says the trading action is both normal, and appropriate for September, and he's been adding some names to his portfolio.

Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

The development of QR-010 is still early but Thursday's preliminary study results were encouraging enough to boost ProQR's stock price.

Important clinical trial results in Alzheimer's, cancer and Crohn's disease and a big FDA decision for Sarepta are expected before the end of the year.

These stocks trading for less than $10 a share look ready to trade higher from current levels.

Advancing the new Vertex drugs into the clinic should also quiet, but not eliminate, investor concerns about competitors closing the gap on the company's market-dominant position in cystic fibrosis treatments.

The company announced its 2015 business outlook on Sunday ahead of its presentation at the J.P. Morgan Healthcare Conference.

The billionaire and crypto investor was in business with Voyager Digital which went bankrupt early July.

The builder confidence index breached the break-even measure of 50 in August for the first time since May 2020.

China is a crucial country for Tesla for its domination of the market of electric vehicles.